GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA

被引：0
|
作者：
Sehn, L. [1 ,2 ]
Chua, N. [3 ]
Mayer, J. [4 ]
Dueck, G. [5 ]
Trneny, M. [6 ]
Bouabdallah, K. [7 ]
Fowler, N. [8 ]
Delwail, V. [9 ]
Press, O. [10 ]
Salles, G. [11 ]
Gribben, J. [12 ]
Lennard, A. [3 ]
Lugtenburg, P. [13 ]
Franklin, N. [14 ]
Wassner-Fritsch, E. [15 ]
Fingerle-Rowson, G. [15 ]
Cheson, B. [16 ]
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[4] Brno & Masaryk Univ, Univ Hosp, Brno, Czech Republic
[5] BC Canc Agcy, Kelowna, Kelowna, BC, Canada
[6] Charles Univ Prague, Gen Hosp, Prague, Czech Republic
[7] CHU Haut Leveque, Pessac, France
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] Univ Hosp, INSERM, Poitiers, France
[10] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[11] Hosp Civils Lyon, Pierre Benite, France
[12] Queen Mary Univ London, Barts Canc Inst, London, England
[13] Erasmus MC Canc Inst, Rotterdam, Netherlands
[14] F Hoffmann La Roche Ltd, Welwyn Garden City, Herts, England
[15] F Hoffmann La Roche Ltd, Basel, Switzerland
[16] Georgetown Univ Hosp, Washington, DC 20007 USA
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
LB691
引用
收藏
页码：273 / 273
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF BENDAMUSTINE VERSUS IBRITUMOMAB TIUXETAN IN THE TREATMENT OF RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA IN CANADA
    Lachaine, J.
    Beauchemin, C.
    Mathurin, K.
    Aissa, F.
    VALUE IN HEALTH, 2013, 16 (03) : A141 - A142
  • [32] A phase II study of single-agent bendamustine in rituximab-refractory B-cell non-Hodgkin's lymphoma
    Forero-Torres, Andres
    Cohen, Philip
    Cheson, Bruce D.
    Robinson, K. Sue
    La Casce, Ann S.
    Fayad, Luis
    Camacho, Elber S.
    Williams, Michael E.
    van der Jagt, Richard H.
    Friedberg, Jonathan W.
    ANNALS OF ONCOLOGY, 2006, 17 : 203 - 203
  • [33] Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study
    Gibiansky, Ekaterina
    Gibiansky, Leonid
    Buchheit, Vincent
    Frey, Nicolas
    Brewster, Michael
    Fingerle-Rowson, Gunter
    Jamois, Candice
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 1935 - 1945
  • [34] Introduction: Treatment of patients with rituximab-refractory indolent non-hodgkin's lymphoma
    Gregory, Stephanie A.
    SEMINARS IN HEMATOLOGY, 2007, 44 (03) : S1 - S1
  • [35] A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma
    Luminari, Stefano
    Goldaniga, Maria
    Cesaretti, Marina
    Orsucci, Lorella
    Tucci, Alessandra
    Pulsoni, Alessandro
    Salvi, Flavia
    Arcaini, Luca
    Carella, Angelo Michele
    Tedeschi, Alessandra
    Pinto, Antonello
    Stelitano, Caterina
    Baldini, Luca
    LEUKEMIA & LYMPHOMA, 2016, 57 (04) : 880 - 887
  • [36] A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study
    Matsumoto, Kimihiro
    Takayama, Nobuyuki
    Aisa, Yoshinobu
    Ueno, Hironori
    Hagihara, Masao
    Watanabe, Kentaro
    Nakaya, Aya
    Chen, Kenko
    Shimizu, Takayuki
    Tsukada, Yuiko
    Yamada, Yuji
    Nakazato, Tomonori
    Ishida, Akaru
    Miyakawa, Yoshitaka
    Yokoyama, Kenji
    Nakajima, Hideaki
    Masuda, Yoshihiro
    Yano, Takahiro
    Okamoto, Shinichiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 554 - 562
  • [37] A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study
    Kimihiro Matsumoto
    Nobuyuki Takayama
    Yoshinobu Aisa
    Hironori Ueno
    Masao Hagihara
    Kentaro Watanabe
    Aya Nakaya
    Kenko Chen
    Takayuki Shimizu
    Yuiko Tsukada
    Yuji Yamada
    Tomonori Nakazato
    Akaru Ishida
    Yoshitaka Miyakawa
    Kenji Yokoyama
    Hideaki Nakajima
    Yoshihiro Masuda
    Takahiro Yano
    Shinichiro Okamoto
    International Journal of Hematology, 2015, 101 : 554 - 562
  • [38] Interim results of a phase III study of bendamustine/rituximab versus R-CHOP as first-line therapy for patients with indolent non-Hodgkin lymphoma
    Jagannath, Sundar
    Cunningham, Sonia
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (01): : 13 - 14
  • [39] Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial
    Kambhampati, Swetha
    Fakhri, Bita
    Ai, Weiyun Z.
    Kaplan, Lawrence D.
    Tuscano, Joseph M.
    Wieduwilt, Matthew J.
    Sudhindra, Akshay
    Cavallone, Erika
    Reiner, Jesika
    Aoun, Charlie
    Castillo, Miguel
    Martinelli, Michelle
    Ta, Teresa
    Le, Diem
    Padilla, Michelle
    Crawford, Erika
    Andreadis, Charalambos B.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : 139 - 146
  • [40] Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-hodgkin's lymphoma
    van der Jagt, Richard H.
    Cohen, Philip
    Cheson, Bruce
    Tulpule, Anil
    Herst, Jordan A.
    Lemieux, Bernard
    Schwartzberg, Lee S.
    Robinson, K. Sue
    Oliver, Jennifer W.
    Williams, Michael E.
    CANCER INVESTIGATION, 2007, 25 : 35 - 36
12345